Fundraising Fox

Nortis

Seattle, US · Founded 2007 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

Nortis was founded in 2007 by Thomas Neumann.

TNThomas Neumann
Thomas NeumanninFounder
AC
Alan C. NelsonNamed on SEC filing

Board

WL
Walter L. RobbBoard director
SK
Sharon K. EversonBoard director
KH
Kriss HammondBoard director

Investors · 1

SeaChange$250K – $1M

Reported raises · per SEC filings

Form D private placements

$13M disclosed across 10 rounds · 2012–2022

▶$6MraisedAug 2022 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Makoto ShintaniDirector
  • Greg CoronaDirector
  • Susan PrestonDirector
  • Thomas NeumannExecutive Officer, Director
  • Paul ConleyDirector
Offering amount
$9.5M
Amount sold
$6M
First sale
Aug 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedJan 2022 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul ConleyDirector
  • Thomas NeumannExecutive Officer, Director
  • Susan PrestonDirector
  • Greg CoronaDirector
Offering amount
$3M
Amount sold
$1.5M
First sale
Jan 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedJun 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Greg CoronaDirector
  • Susan PrestonDirector
  • Paul ConleyDirector
  • Thomas NeumannExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Jun 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedJun 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul ConleyDirector
  • Greg CoronaDirector
  • Thomas NeumannExecutive Officer, Director
  • Susan PrestonDirector
Offering amount
$1M
Amount sold
$1M
First sale
Jun 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$323.2KraisedJul 2017 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan C. NelsonExecutive Officer, Director
  • Thomas NeumannExecutive Officer, Director
  • Mary Ellen HarrisonDirector
  • Walter L. RobbDirector
  • Sharon K. EversonDirector
Offering amount
$500K
Amount sold
$323.2K
First sale
Aug 2016
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.5KraisedJun 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas NeumannExecutive Officer, Director
  • Sharon K. EversonDirector
  • Walter L. RobbDirector
  • Mary Ellen HarrisonDirector
  • Alan C. NelsonExecutive Officer, Director
Offering amount
$5M
Amount sold
$12.5K
First sale
Aug 2016
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$408.8KraisedMar 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sharon K. EversonDirector
  • Walter L. RobbDirector
  • Kriss HammondDirector
  • Thomas NeumannExecutive Officer, Director
  • Alan C. NelsonExecutive Officer, Director
Offering amount
$3.4M
Amount sold
$408.8K
First sale
Mar 2015
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedJul 2014 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas NeumannExecutive Officer, Director
  • Kriss HammondDirector
  • Walter L. RobbDirector
  • Alan C. NelsonExecutive Officer, Director
  • Sharon K. EversonDirector
Offering amount
$2M
Amount sold
$1M
First sale
Jun 2014
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 12 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$275.5K
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$1.7M
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2.3M
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$252.1K
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$331.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$300K
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1.4M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2016$365K
National Institutes of Health (NIH)National Institutes of HealthPhase II2015$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$225K
National Institutes of Health (NIH)National Institutes of HealthPhase II2014$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2013$300K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Nortis, a Seattle-based startup developing 'organ-on-a-chip' tech, raises cash – GeekWiregeekwire.com · Aug 2022Woodinville biotech lands $6M with plans to raise more, filing shows - Puget Sound Business Journalbizjournals.com · Aug 2022Nortis Awarded $688K NIH Phase II SBIR Fast Track Grant to Develop Living Model of Human Blood-Brain Barrierprnewswire.com · Aug 2017

Frequently asked questions

Who founded Nortis?
Nortis was founded by Thomas Neumann in 2007.
Who are Nortis's investors?
Nortis's investors include SeaChange.
How much funding has Nortis raised?
Nortis has disclosed $13M raised across 10 rounds.
Where is Nortis headquartered?
Nortis is headquartered in Seattle, US.